CortiSlim warning letter
This article was originally published in The Tan Sheet
Promotional materials for CortiSlim dietary supplement feature claims that cause the product to be misbranded under the FD&C Act, FDA tells Window Rock Enterprises in an Aug. 19 warning letter. Claims such as "Controls cortisol levels within a healthy range" on the product label, brochure, start guide and website "are not supported by reliable scientific evidence" and therefore are false and misleading, the agency says. Window Rock had 15 days to respond with appropriate measures...
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.